Azizi Ali, Diaz-Mitoma Francisco
Variation Biotechnologies Inc., 22 de Varennes, Suite 210, Gatineau, QC J8T 8R1, Canada.
J Pept Sci. 2007 Dec;13(12):776-86. doi: 10.1002/psc.896.
Synthetic peptide vaccines have potential to control viral infections. Successful experimental models using this approach include the protection of mice against the lethal Sendai virus infection by MHC class I binding CTL peptide epitope. The main benefit of vaccination with peptide epitopes is the ability to minimize the amount and complexity of a well-defined antigen. An appropriate peptide immunogen would also decrease the chance of stimulating a response against self-antigens, thereby providing a safer vaccine by avoiding autoimmunity. In general, the peptide vaccine strategy needs to dissect the specificity of antigen processing, the presence of B-and T-cell epitopes and the MHC restriction of the T-cell responses. This article briefly reviews the implications in the design of peptide vaccines and discusses the various approaches that are applied to improve their immunogenicity.
合成肽疫苗具有控制病毒感染的潜力。使用这种方法的成功实验模型包括通过MHC I类结合CTL肽表位保护小鼠免受致死性仙台病毒感染。用肽表位进行疫苗接种的主要好处是能够将明确抗原的数量和复杂性降至最低。合适的肽免疫原还会降低刺激针对自身抗原的反应的可能性，从而通过避免自身免疫提供更安全的疫苗。一般来说，肽疫苗策略需要剖析抗原加工的特异性、B细胞和T细胞表位的存在以及T细胞反应的MHC限制。本文简要回顾了肽疫苗设计中的相关问题，并讨论了用于提高其免疫原性的各种方法。
